2-methoxyestradiol inhibits Barrett's esophageal adenocarcinoma growth and differentiation through differential regulation of the β-catenin-E-cadherin axis

Molecular Cancer Therapeutics

Volumn 9, Issue 3, 2010, Pages 523-534

  Kambhampati, Suman ^a,b   Banerjee, Snigdha ^a,b   Dhar, Kakali ^a,b   Mehta, Smita ^a,b   Haque, Inamul ^a,b   Dhar, Gopal ^a,b   Majumder, Monami ^a,b   Ray, Gibanananda ^a   Vanveldhuizen, Peter J ^a,b   Banerjee, Sushanta K ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; BETA CATENIN; PROTEIN BAX; PROTEIN BCL 2; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN BIC1; CONTROLLED STUDY; DRUG MECHANISM; ESOPHAGEAL ADENOCARCINOMA; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STABILITY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BARRETT ESOPHAGUS; BETA CATENIN; CADHERINS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; ESOPHAGEAL NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949671855     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0845     Document Type: Article

References (49)

1. Hamilton SR, Smith RR, Cameron JL. Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. Hum Pathol 1988;19:942-8.
2. Cossentino MJ, Wong RK. Barrett's esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis 2003;14:128-35.
3. Casson AG, Williams L, Guernsey DL. Epidemiology and molecular biology of Barrett esophagus. Semin Thorac Cardiovasc Surg 2005;17:284-91.
4. McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 2004;64:1561-9.
5. Mooney MM. Neoadjuvant and adjuvant chemotherapy for esophageal adenocarcinoma. J Surg Oncol 2005;92:230-8.
6. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52.
7. Mooberry SL. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat 2003;6:355-61.
8. Zoubine MN, Weston AP, Johnson DC, Campbell DR, Banerjee SK. 2-Methoxyestradiol-induced growth suppression and lethality in estrogen-responsive MCF-7 cells may be mediated by downregulation of p34cdc2 and cyclin B1 expression. Int J Oncol 1999;15:639-46.
9. Banerjee SN, Sengupta K, Banerjee S, Saxena N, Banerjee SK. 2-methoxyestradiol exhibits a biphasic effect on VEGF-A in tumor cells and upregulation is mediated through ER-a: A possible signaling pathway associated with the impact of 2-ME2 on proliferative cells. Neoplasia 2003;5:417-26.
10. Shimada K, Nakamura M, Ishida E, Kishi M, Konishi N. Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 2003;24:1067-75.
11. Davoodpour P, Landstrom M. 2-Methoxyestradiol-induced apoptosis in prostate cancer cells requires Smad7. J Biol Chem 2005;280:14773-9.
12. Sattler M, Quinnan LR, Pride YB, et al. 2-Methoxyestradiol alters cell motility, migration, and adhesion. Blood 2003;102:289-96.
13. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A 1994;91:3964-8.
14. Mabjeesh NJ, Escuin D, Lavallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75.
15. Perez-Stable C. 2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells. Cancer Lett 2006;231:49-64.
16. Ray G, Dhar G, Van Veldhuizen PJ, et al. Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways. Biochemistry 2006;45:3703-13.
17. James J, Murry DJ, Treston AM, et al. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 2007;25:41-8.
18. Nelson WJ, Nusse R. Convergence of Wnt, β-catenin, and cadherin pathways. Science 2004;303:1483-7.
19. Wijnhoven BP, Dinjens WN, Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 2000;87:992-1005.
20. Behrens J, Lustig B. The Wnt connection to tumorigenesis. Int J Dev Biol 2004;48:477-87.
21. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
22. Kambhampati S, Li Y, Verma A, et al. Activation of protein kinase C δ by all-trans-retinoic acid. J Biol Chem 2003;278:32544-51.
23. Sengupta K, Banerjee S, Dhar K, et al. WISP-2/CCN5 is involved as a novel signaling intermediate in phorbol ester-protein kinase Ca-mediated breast tumor cell proliferation. Biochemistry 2006;45:10698-709.
24. Banerjee S, Sengupta K, Dhar K, et al. Breast cancer cells secreted platelet-derived growth factor-induced motility of vascular smooth muscle cells is mediated through neuropilin-1. Mol Carcinog 2006;45:871-80.
25. Reed JC. Bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicol Lett 1995;82-83:155-8.
26. Isenmann S, Wahl C, Krajewski S, Reed JC, Bahr M. Up-regulation of Bax protein in degenerating retinal ganglion cells precedes apoptotic cell death after optic nerve lesion in the rat. Eur J Neurosci 1997;9:1763-72.
27. Dhar G, Banerjee S, Dhar K, et al. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. Cancer Res 2008;68:4580-7.
28. Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science 2000;287:1606-9.
29. 2-M and apoptosis. Mol Biol Cell 2003;14:2844-60.
30. 1 cell cycle regulators. Mol Biol Cell 2000;11:3509-23.
31. Pierce M, Wang C, Stump M, Kamb A. Overexpression of the β-catenin binding domain of cadherin selectively kills colorectal cancer cells. Int J Cancer 2003;107:229-37.
32. Sadot E, Simcha I, Shtutman M, Ben Ze'ev A, Geiger B. Inhibition of β-catenin-mediated transactivation by cadherin derivatives. Proc Natl Acad Sci U S A 1998;95:15339-44.
33. Gottardi CJ, Wong E, Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting β-catenin signaling in an adhesion-independent manner. J Cell Biol 2001;153:1049-60.
34. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R. E-cadherin binding prevents β-catenin nuclear localization and β-catenin/LEF-1-mediated transactivation. J Cell Sci 1999;112:1237-45.
35. Campbell IG, Qiu W, Polyak K, Haviv I. Breast-cancer stromal cells with TP53 mutations. N Engl J Med 2008;358:1634-5.
36. Mahidhara RS, Queiroz De Oliveira PE, Kohout J, et al. Altered trafficking of Fas and subsequent resistance to Fas-mediated apoptosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma. J Surg Res 2005;123:302-11.
37. 2-M arrest and inducing apoptosis. Food Chem Toxicol 2008;46:2042-53.
38. Valette A, Gas N, Jozan S, Roubinet F, Dupont MA, Bayard F. Influence of 12-O-tetradecanoylphorbol-13-acetate on proliferation and maturation of human breast carcinoma cells (MCF-7): relationship to cell cycle events. Cancer Res 1987;47:1615-20.
39. Dahut WL, Lakhani NJ, Gulley JL, et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 2006;5:22-7.
40. Sweeney C, Liu G, Yiannoutsos C, et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 2005;11:6625-33.
41. Koppert LB, Wijnhoven BP, van Dekken H, Tilanus HW, Dinjens WN. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 2005;92:169-90.
42. Fagotto F, Gumbiner BM. Cell contact-dependent signaling. Dev Biol 1996;180:445-54.
43. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996;84:345-57.
44. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 2005;24:7443-54.
45. Fagotto F, Funayama N, Gluck U, Gumbiner BM. Binding to cadherins antagonizes the signaling activity of β-catenin during axis formation in Xenopus. J Cell Biol 1996;132:1105-14.
46. Wijnhoven BP, Pignatelli M, Dinjens WN, Tilanus HW. Reduced p120ctn expression correlates with poor survival in patients with adenocarcinoma of the gastroesophageal junction. J Surg Oncol 2005;92:116-23.
47. Washington K, Chiappori A, Hamilton K, et al. Expression of β-catenin, α-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. Mod Pathol 1998;11:805-13.
48. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia- adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol 1998;152:135-44.
49. Swami S, Kumble S, Triadafilopoulos G. E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study. Am J Gastroenterol 1995;90:1808-13.